Lack of a role for MRPI in platinum drug resistance in human ovarian cancer cell lines
1998

Role of MRP1 in Platinum Drug Resistance in Ovarian Cancer

Sample size: 5 publication 10 minutes Evidence: moderate

Author Information

Author(s): SY Sharp, V Smith, S Hobbs, LR Kelland

Primary Institution: CRC Centre for Cancer Therapeutics, The Institute of Cancer Research

Hypothesis

Does MRP1 play a significant role in platinum resistance in human ovarian carcinoma cell lines?

Conclusion

The study suggests that MRP1 does not play a significant role in platinum resistance in the human tumor cell lines investigated.

Supporting Evidence

  • MRP1 was not overexpressed in any of the ovarian cancer cell lines studied.
  • Transfected MRP1 did not confer resistance to platinum drugs in the SKOV3 cell line.
  • Reduction of GSH levels increased cisplatin sensitivity across all cell lines.

Takeaway

The researchers looked at how a protein called MRP1 affects how well ovarian cancer cells respond to a common cancer drug. They found that MRP1 doesn't really help the cancer cells resist the drug.

Methodology

The study involved Western blotting to assess MRP1 expression and cytotoxicity assays to evaluate drug resistance in various ovarian cancer cell lines.

Limitations

The study is limited to specific human ovarian carcinoma cell lines and may not be generalizable to all cancer types.

Participant Demographics

Human ovarian carcinoma cell lines were used, including variants with acquired cisplatin resistance.

Statistical Information

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication